aminosalicylic acid

(redirected from Aminosalicylate)
Also found in: Medical.
Related to Aminosalicylate: Pentasa

a·mi·no·sal·i·cyl·ic acid

 (ə-mē′nō-săl′ĭ-sĭl′ĭk, ăm′ə-nō-)
References in periodicals archive ?
Tenders are invited for Powder Granules Sod Aminosalicylate 60 Percent-100Gm
Aminosalicylate compounds are frequently prescribed drugs for the control of IBD symptoms in humans.
If the inflammation is confined to the rectum or lower part of the colon, your doctor may prescribe aminosalicylate drugs for you to self-administer in the form of an enema or suppositories.
Relapsing tubulointerstitial nephritis in an adolescent with inflammatory bowel disease without aminosalicylate exposure.
AbbVie Inc (NYSE:ABBV), a research-based biopharmaceutical company, announced on Tuesday the approval by Health Canada of HUMIRA (adalimumab) for reducing signs and symptoms and inducing and maintaining clinical remission in paediatric patients 13 to 17 years of age weighing 40 kilograms or more with severely active Crohn's disease and/or who have had an inadequate response or were intolerant to conventional therapy (a corticosteroid and/or aminosalicylate and/or an immunosuppressant) and/or a tumour necrosis factor alpha antagonist.
The aminosalicylate group of drugs has become the first-line therapy to induce and maintain remission for mild to moderate inflammatory bowel disease (mild to moderate UC and mild CD) (4-5).
Corticosteroid use can reduce inflammation and induce remission, particularly in patients who have severe active disease or in those who have not responded to aminosalicylate therapy.
This is in line with the findings of others that mesalazine, the only aminosalicylate administered during the study, has low interfering potential (40-42).
Tenders are invited for Tablet/Capsule Mesalamine 5 Aminosalicylate Acid 800Mg
All patients had been receiving stable aminosalicylate or thiopurine therapy, and continued to receive this therapy during the trial.
0) NA# Treatment Patient Antimicrobial duration, age, y/sex drug therapy outcome 19/M INH, RFP, EMB; 9 mo, cured ([dagger]) then INH, RFP 39/F INH, RFP, EMB, 1 y, cured ([section]) PZA; then INH, RFP 43/M ** CLR, CIP; then 1 y, relapse; INH, RFP, EMB, 8 mo, cured PZA, CLR, CIP * AMK, amikacin; R, resistant; CYC, cycloserine; S, susceptible; CIP, ciprofloxacin; CLF, clofazimine; CLR, clarithromycin; EMB, ethambutol; INH, isoniazid; I, intermediate; PAS, para/ aminosalicylate sodium; PRO, prothionamide; RFB, rifabutin; RIF, rifampin; STR, streptomycin; RFP, rifapentine; DOX, doxycycline; ETH, ethionamide; LZD, linezolid; MOX, moxifloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available; PZA, pyrazinamide.
The label describes three studies of more than 1,400 adults with moderately to severely active Crohn's; nearly 80% of patients continued treatment with at least one aminosalicylate, corticosteroid, and / or immunomodulatory agent.